Excellent point. I didn't think of that. If pona is proves effective at lower doses (or no AEs with screening, or initial dose of 45 with drop to 30 or less shortly thereafter), the case for first line use could actually be quite plausible.
Yes, I wasted $31.5 again and bought the article (roughly equal to the cost of a respectable, but not spectacular bottle of Pomerol). I will atempt to deciper and share (always respectful of copyright resreictions) in next 24 hrs. Btw, this is less hard on my liver than the wine, thus a good investment in my view.
"...it would emphasize that doctors should use the most powerful TKI first, rather than use a weak one and later switch to a stronger one."
If the safety issue is overcome ---- and it seems to be so far -- then I think this point is important. If I had the disease, it would certainly be what I would want. It strikes me as malpractice to make a patient go through a series of relapses before pona.
News 
Market Data 
Discover 
